Lakefront Biotherapeutics NV has announced a new share repurchase program of up to €50 million, following the successful completion of its initial buyback program. This strategic move is designed to enhance shareholder value and reflects the company's confidence in its future prospects.

On November 16, 2026, the company revealed that it had completed its initial €50 million share repurchase program, during which it bought back approximately 1.99 million ordinary shares. These shares are now held as treasury shares.

The new share repurchase program will be executed by Morgan Stanley & Co International PLC, acting as an independent financial intermediary. The purchases will occur in the open market on Euronext, adhering to the terms approved by the Extraordinary Shareholders' Meeting on April 28, 2026.

“Having successfully completed our initial buyback, we believe our current share price does not reflect the value of our business and its future prospects,” stated Aaron Cox, Chief Financial Officer of Lakefront. “This additional €50 million program provides an opportunity to create shareholder value while continuing to invest in our pipeline.”

The company may repurchase up to 4,604,550 ordinary shares under this new program, which will run until March 31, 2027, or until the completion of the mandate.

Lakefront Biotherapeutics is a biotechnology firm focused on developing innovative medicines for patients with serious diseases. The company has established a clinical-stage portfolio in immunology and inflammation, anchored by its lead product candidate, gamgertamig, a potential first-in-class T-cell engager for autoimmune diseases.

This repurchase initiative comes at a time when the pharmaceutical industry is facing intense competition and scrutiny. By investing in its own shares, Lakefront aims to signal confidence in its growth trajectory and the value of its pipeline.

Regular updates regarding the share repurchase program will be provided in accordance with applicable legislation. Lakefront retains the right to suspend or terminate the program at any time, with any such decision being disclosed in a company announcement.

As Lakefront moves forward with this new initiative, it will be interesting to see how it impacts the company's stock performance and investor sentiment in the competitive pharmaceutical landscape.